lindas have a posse
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Many at ASCO obviously loved DCVax!
DCVax top article in JAMA. Attention spread to Nature. Everyone speaking about DCVax.
We are still on target for approval in 2023.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=172171599
13K page views on a tiny OTC website. Obviously there are many interested in DCVax.
Linda Powers will be on the cover of Time Magazine.
Many will read about the NWBO story from Angola Penitentiary.
DCVax the platform for all solid tumors.
New loans do not involve issuing more shares. The lender is only being paid interest not in shares. No dilution.
New loans do not have dilution. Fact.
NWBO are funding the company without dilution as the most recent loan indicates.
We are on track for 2023 approval as management state as their goal:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=172171599
Approval likely this year as management stated in their goals for 2023:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=172171599
Plenty of time for 2023 approval:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=172171599
OTC spoofing explains our share price.
I believe they will uplist on news from MHRA.
Nothing misleading in their PRs which suggest approval this year
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=172171599
Trillion-dollar technology.
Plenty of time for approval this year!
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=172171599
Company said they believe the PIP trial will occur this year:
During 2023, the Company anticipates that additional key areas of focus will include:
commencing the pediatric clinical program required under the PIP
The Company’s approved PIP includes a deferral under which the pediatric trials are anticipated to be undertaken after an MAA application has been submitted.
BP needs NWBO but does NWBO need BP?
Trillion-dollar technology.
Well said bio. The shorts tried to destroy Northwest Biotherapeutics. Many cancer patients died as a result of their actions.
Management own a large percentage of the company so will benefit immensely from an appreciation in the stock price. I don't care what happened in 2018 as we are not the same company.
Short sellers drove us to OTC.
Was able to locate the original $NWBO Phase Five note which crashed the stock & led to its Nasdaq delisting in 2015 - link below.
— Jssr (@juliaskripkaser) October 16, 2020
This ultimate fraud is once again flying high on false promises to new shareholders. Only fair that they know what this is🤷♀️ https://t.co/DHPEjYENlm
Management haven't sold any shares. That's what matters.
Management have not sold any shares. They seem committed to the company’s future.
If you want management to work for free that sounds unreasonable in a capitalist economy.
Should management work for free?
Any owner in a company should be paid for the fruits of their labor.
We are not communists.
Unlike Novocure management in Northwest still own shares thus they want to see the price increase.
Management own more shares in the company than any poster on this forum.
Logic suggests they want a higher share price.
In fact CVM missed their endpoints. You won't see their results in JAMA or any peer-reviewed journal.
Landmark Trial Results!
Les may get a lot of inquiries when he speaks on the Big Biz Show. I would rather we be in WSJ but there's plenty of time for that when Citadel et al pay us $2 billion to settle this year. That would be quite a story if it coincided with MHRA approval this fall.
If NWBO treated 2M patients then that's around $700 a share.
The only limitations here are scaling up to meet demand. The unmet greenfield market exists. No competition.
If the Big Biz Show has syndication into 50M homes then this seems like cheap advertising. It's not my ideal format but there will always be time for us to be in the WSJ yet again.
So quickly we forget that Northwest Biotherapeutics was on the front page of WSJ last year.
Excellent points, BB!
The challenges we must overcome to being the platform for all solid tumors are all manufacturing related not whether we will have enough funding. All very good points, Gary!
The hardest working professors generally have clutter throughout their offices. I bet most of those documents in Les' office are academic and financial publications.
Institutional Investors care about the billions in revenue which DCVax will bring to shareholders not that Les Goldman appeared on this ridiculous program.
I was not the first to report this development.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=159486797
Charles River Labs, then Cognate, mentioned Northwest Biotherapeutics as a client in their PILOTS tax credit application.
We are a major client otherwise we wouldnt be one of the two mentioned in their tax credit application!
https://www.bizjournals.com/memphis/news/2020/11/13/cognate-bioservices-plans-huge-new-investment.html
Cognate's EDGE application says the company also recently "manufactured the product for the world's largest clinical trial for a treatment for glioblastoma multiforme, considered the most aggressive form of brain cancer."
Its clients include AstraZeneca, Atara Biotherapeutics Inc. and Northwest Biotherapeutics Inc.
Les Goldman has been instrumental in ensuring our angel investors stay with this company.
He certainly comes from another era but then again he's part of the team which defeated Glioblastoma.
They will bring this through the finish line. We may not understand their methods but that's acceptable given their accomplishments.
They always deliver in my opinion.
Thank you ATL!
That's certainly possible. This isn't my preferred venue but it could be a stop gap until we have more news to report.
That's right Doc. My medium term investment basis involved nrGBM only though as DCVax begins to treat other indications the possibilities increase exponentially.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=172073359
After watching Les Goldman on Big Biz for 50 times it shows up in your browser through osmosis.
The company does pay for these advertisements as they're listed in our OTC annual report. I am not a huge fan, at all, but I believe the stock did run the last time Les debased himself on this ridiculous program. I guess some do watch it after enjoying reruns of Matlock.